Results 201 to 210 of about 29,030 (239)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

Journal of Neurology, Neurosurgery and Psychiatry, 2020
Objective The Tysabri Observational Programme (TOP), which began >10 years ago, is an open-label, multinational, prospective observational study evaluating the long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis ...
Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.

Lancet Neurology, 2022
BACKGROUND Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal leukoencephalopathy.
J. Foley, G. Defer, L. Z. Ryerson, Jeffrey A. Cohen, D. Arnold, H. Butzkueven, G. Cutter, G. Giovannoni, J. Killestein, H. Wiendl, K. Smirnakis, Shan Xiao, G. Kong, R. Kuhelj, N. Campbell   +14 more
semanticscholar   +1 more source

Natalizumab

Neurology, 2009
Since it first came to trial, natalizumab (Tysabri) has kept the multiple sclerosis (MS) world in a constant state of flux. Shortly after its initial launch, the appearance of three cases of progressive multifocal leukoencephalopathy (PML), a devastating infection of the CNS caused by the JC virus, resulted in the drug’s withdrawal from the market ...
Nicoline, Schiess, Peter A, Calabresi
openaire   +3 more sources

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Annals of Neurology, 2020
Novel, highly effective disease‐modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking.
Peter Alping, Johan Askling, Joachim Burman   +2 more
exaly   +2 more sources

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

Journal of Neurology Neurosurgery & Psychiatry, 2022
Background To compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with relapsing–remitting multiple sclerosis switching from fingolimod.
Chao Zhu, Zhen Zhou, I. Roos, Daniele Merlo, T. Kalincik, S. Ozakbas, O. Skibina, J. Kuhle, S. Hodgkinson, C. Boz, R. Alroughani, J. Lechner-Scott, M. Barnett, G. Izquierdo, A. Prat, D. Horáková, E. Kubala Havrdová, R. Macdonell, F. Patti, S. Khoury, M. Slee, R. Karabudak, M. Onofrj, V. van Pesch, J. Prevost, M. Monif, V. Jokubaitis, A. van der Walt, H. Butzkueven   +28 more
semanticscholar   +1 more source

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Lancet Neurology, The, 2017
Harold Koendgen
exaly   +2 more sources

Natalizumab update

American Journal of Health-System Pharmacy, 2007
The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of natalizumab are reviewed.Natalizumab, the first commercially available selective adhesion-molecule inhibitor, is approved as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis (MS ...
openaire   +2 more sources

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Multiple Sclerosis
Background: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking. Objectives: To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing ...
I. Roos, S. Sharmin, C. Malpas, S. Ozakbas, J. Lechner-Scott, S. Hodgkinson, R. Alroughani, Sara Eichau Madueño, C. Boz, A. van der Walt, H. Butzkueven, K. Buzzard, O. Skibina, M. Foschi, F. Grand'Maison, N. John, P. Grammond, M. Terzi, J. Prevost, M. Barnett, G. Laureys, L. Van Hijfte, José Luis Sanchez-Menoyo, Yolanda Blanco, Jiwon Oh, P. McCombe, Cristina Ramo Tello, A. Soysal, A. Prat, P. Duquette, B. Yamout, S. Khoury, V. van Pesch, Richard Macdonell, M. José Sá, M. Slee, J. Kuhle, Davide Maimone, D. Spitaleri, Barbara Willekens, Abdallah Al Asmi, E. Tallantyre, Neil Robertson, Alasdair J Coles, J. W. L Brown, T. Kalincik   +45 more
semanticscholar   +1 more source

Personalized extended interval dosing of natalizumab in MS

Neurology, 2020
Objective To determine whether natalizumab efficacy is maintained when switching to personalized extended interval dosing based on individual natalizumab trough concentrations in patients with relapsing-remitting multiple sclerosis (RRMS).
Z. V. van Kempen, E. Hoogervorst, M. Wattjes, N. Kalkers, J. Mostert, Birgit I. Lissenberg-Witte, A. de Vries, A. ten Brinke, B. van Oosten, F. Barkhof, C. Teunissen, B. Uitdehaag, T. Rispens, J. Killestein   +13 more
semanticscholar   +1 more source